Company news

Alzamend Neuro, Inc. news in 2026

Alzamend Neuro, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

August 20, 2026

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

August 4, 2026

Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)

July 22, 2026

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

April 6, 2026

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

March 25, 2026

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

March 15, 2026

Decks in 2026